title: Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.
authors.forename: R D
authors.initials: RD
authors.lastname: Carr
authors.forename: H L
authors.initials: HL
authors.lastname: Katzeff
authors.forename: C M
authors.initials: CM
authors.lastname: Alexander
authors.forename: J P
authors.initials: JP
authors.lastname: Berger
authors.forename: S S
authors.initials: SS
authors.lastname: Xu
authors.forename: N
authors.initials: N
authors.lastname: Thornberry
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008687:Metformin / Q000008:administration & dosage*; D009570:Nitriles / Q000008:administration & dosage* / Q000494:pharmacology*; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D052216:Glucagon-Like Peptide 1; D008687:Metformin; D018819:Dipeptidyl Peptidase 4; D000218:Adamantane